<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39298596</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>385</Volume><Issue>6715</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>20</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Psychedelic research at a crossroads.</ArticleTitle><Pagination><StartPage>1255</StartPage><MedlinePgn>1255</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.adt1024</ELocationID><Abstract><AbstractText>There is an urgent need to develop better treatments for mental health conditions that affect one in every eight people in the world. To combat this concern, psychedelic drugs have been combined with psychotherapy and studied in clinical trials in the United States and Europe. Psychedelics are hallucinogenic drugs that alter brain activity and facilitate altered states of consciousness. The proposed benefits of psychedelic-assisted therapy (PAT) include relatively short treatment times and stronger effects compared to other treatments. Although results of trials using MDMA for trauma or psilocybin for depression are promising, PAT is controversial because many questions about its safety and effectiveness are unanswered. This is evident in the recent ruling by the US Food and Drug Administration against the approval of MDMA therapy for post-traumatic stress disorder and the retraction of several papers about MDMA trials owing to unethical conduct by study therapists and data integrity, among other concerns. This field is at a crossroads, and the research community must address several obstacles to transition from exploratory trials to established, evidence-based treatments while avoiding pitfalls that can hinder advancement.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Armstrong</LastName><ForeName>Stacey B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Stacey B. Armstrong is a senior researcher and associate director at the Center for Psychedelic Drug Research and Education, College of Social Work, The Ohio State University, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Alan K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Alan K. Davis is an associate professor and director at the Center for Psychedelic Drug Research and Education, College of Social Work, The Ohio State University, Columbus, OH, USA and an adjunct professor at the Center for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, USA. davis.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006213">Hallucinogens</NameOfSubstance></Chemical><Chemical><RegistryNumber>KE1SEN21RM</RegistryNumber><NameOfSubstance UI="D018817">N-Methyl-3,4-methylenedioxyamphetamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>2RV7212BP0</RegistryNumber><NameOfSubstance UI="D011562">Psilocybin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017277" MajorTopicYN="N">Drug Approval</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006213" MajorTopicYN="Y">Hallucinogens</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018817" MajorTopicYN="N">N-Methyl-3,4-methylenedioxyamphetamine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011562" MajorTopicYN="N">Psilocybin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="Y">Psychotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="Y">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>20</Day><Hour>1</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>20</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>19</Day><Hour>14</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39298596</ArticleId><ArticleId IdType="doi">10.1126/science.adt1024</ArticleId></ArticleIdList></PubmedData></PubmedArticle>